Nature Communications (May 2023)

Nucleocapsid-specific T cell responses associate with control of SARS-CoV-2 in the upper airways before seroconversion

  • Tabea M. Eser,
  • Olga Baranov,
  • Manuel Huth,
  • Mohammed I. M. Ahmed,
  • Flora Deák,
  • Kathrin Held,
  • Luming Lin,
  • Kami Pekayvaz,
  • Alexander Leunig,
  • Leo Nicolai,
  • Georgios Pollakis,
  • Marcus Buggert,
  • David A. Price,
  • Raquel Rubio-Acero,
  • Jakob Reich,
  • Philine Falk,
  • Alissa Markgraf,
  • Kerstin Puchinger,
  • Noemi Castelletti,
  • Laura Olbrich,
  • Kanika Vanshylla,
  • Florian Klein,
  • Andreas Wieser,
  • Jan Hasenauer,
  • Inge Kroidl,
  • Michael Hoelscher,
  • Christof Geldmacher

DOI
https://doi.org/10.1038/s41467-023-38020-8
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Despite intensive research since the emergence of SARS-CoV-2, it has remained unclear precisely which components of the early immune response protect against the development of severe COVID-19. Here, we perform a comprehensive immunogenetic and virologic analysis of nasopharyngeal and peripheral blood samples obtained during the acute phase of infection with SARS-CoV-2. We find that soluble and transcriptional markers of systemic inflammation peak during the first week after symptom onset and correlate directly with upper airways viral loads (UA-VLs), whereas the contemporaneous frequencies of circulating viral nucleocapsid (NC)-specific CD4+ and CD8+ T cells correlate inversely with various inflammatory markers and UA-VLs. In addition, we show that high frequencies of activated CD4+ and CD8+ T cells are present in acutely infected nasopharyngeal tissue, many of which express genes encoding various effector molecules, such as cytotoxic proteins and IFN-γ. The presence of IFNG mRNA-expressing CD4+ and CD8+ T cells in the infected epithelium is further linked with common patterns of gene expression among virus-susceptible target cells and better local control of SARS-CoV-2. Collectively, these results identify an immune correlate of protection against SARS-CoV-2, which could inform the development of more effective vaccines to combat the acute and chronic illnesses attributable to COVID-19.